Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25087871 | 1.00 | HSD17B10 (0.48) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL21523427 | 0.99 | HSD17B10 (0.47) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL21523430 | 0.99 | HSD17B10 (0.47) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| SCHEMBL25424456 | 0.95 | HSD17B10 (0.47) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| SCHEMBL25424454 | 0.95 | HSD17B10 (0.47) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL25424488 | 0.93 | HSD17B10 (0.46) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL25424490 | 0.93 | HSD17B10 (0.46) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| Cadaverine Tartrate SCHEMBL29263443 | 0.90 | HSD17B10 (0.49) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| Tartaric Acid SCHEMBL31024302 | 0.90 | HSD17B10 (0.49) | HSD17B10BCL2L1KMT2AALDH1A1MAPT | |
| Tartaric Acid SCHEMBL30165576 | 0.90 | HSD17B10 (0.49) | HSD17B10BCL2L1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368603-A1 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2025-12-04 | — | — | US | claimed |
| CN-118139835-A | Method for preparing apoptosis inducer | 艾伯维公司 | 2024-06-04 | — | — | CN | claimed |
| EP-2307393-B1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | ABBOTT LAB (US) | 2013-04-10 | — | — | EP | claimed |
| US-8168784-B2 | Processes to make apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-01 | — | — | US | claimed |
| US-20090318689-A1 | Processes To Make Apoptosis Promoters | ABBOTT LABORATORIES (US) | 2009-12-24 | — | — | US | claimed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250368603-A1 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025064952-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-118139835-A | Method for preparing apoptosis inducer | 艾伯维公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2009155386-A1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | ABBOTT LABORATORIES (US) | 2009-12-23 | — | — | WO | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368603-A1 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | BAX, CASP3, AIFM1 | HSD17B10 2911/4885BCL2L1 25/4885KMT2A 4217/4885 |
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | HSD17B10 2782/4885BCL2L1 10/4885KMT2A 4140/4885 |
| US-20090318689-A1 | Processes To Make Apoptosis Promoters | BAX, BCL2, CCAR2 | HSD17B10 826/4885BCL2L1 28/4885KMT2A 3082/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | HSD17B10 2782/4885BCL2L1 10/4885KMT2A 4140/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | HSD17B10 2782/4885BCL2L1 10/4885KMT2A 4140/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | HSD17B10 1017/4885BCL2L1 20/4885KMT2A 3521/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | HSD17B10 1049/4885BCL2L1 3/4885KMT2A 2454/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | HSD17B10 2296/4885BCL2L1 18/4885KMT2A 1794/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | HSD17B10 4429/4885BCL2L1 3/4885KMT2A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.